查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1853617

脐带血处理产品市场按产品类型、应用、最终用户、处理方法、服务供应商和样本类型划分－全球预测，2025-2032年

Umbilical Cord Blood Processing Products Market by Product Type, Application, End User, Processing Method, Service Provider, Sample Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，脐带血处理产品市场规模将成长 39.8 亿美元，复合年增长率为 11.27%。

关键市场统计数据
基准年 2024 16.9亿美元
预计年份：2025年 18.9亿美元
预测年份 2032 39.8亿美元
复合年增长率 (%) 11.27%

随着临床创新、品质要求和业务重点的演变，制定脐带血处理产品的策略背景

本导言旨在为快速发展的脐带血处理产品领域提供背景信息，该领域融合了临床创新、监管演变和运营现代化。细胞疗法和再生医学的进步凸显了精准、高效且无菌的处理方案的重要性，迫使临床、研究和商业相关人员重新思考从采集到储存的整个工作流程。同时，该行业在品管、可追溯性和可扩展性方面也面临日益严格的审查，促使各机构重新审视传统的手工操作方法，并选择能够确保可重复性并降低污染风险的技术。

在此背景下，本报告概述了影响策略选择的关键主题驱动因素：将自动化系统整合到现有实验室基础设施中；区分封闭式和开放式系统结构；以及在可自订的手动套件通讯协定和优先考虑速度和合规性的预包装套件之间进行权衡。报告还提供了一个视角，用于评估最终用户（生物技术公司、医院和诊所以及研究机构）的需求，每个用户在治疗产品线、临床吞吐量和临床实验活动方面都有不同的优先事项。有了这个基础概述，主管们就可以以务实的视角解读后续分析，重点在于营运准备、监管合规性以及跨部门合作的潜力。

技术自动化、通讯协定灵活性和治疗进展如何推动混合策略并重塑临床和研究环境中的处理工作流程

技术、工作流程设计和政策的变革性转变正在重新定义人们对脐带血处理解决方案的期望。自动化不再是小众的增强功能，而是对可重复性、劳动力利用率和污染控制有直接影响的策略性槓桿。旨在最大限度减少操作人员干预并维持无菌屏障的封闭式自动化系统，越来越受到寻求更高通量和更稳定结果的临床实验室的青睐。相较之下，开放式系统保留了客製化方案和流程调整的灵活性，使其非常适合方法客製化至关重要的研究环境和小型临床机构。

手动试剂套件将继续发挥补充作用，尤其是在方案需要适应性或资金投入限制导致自动化普及延迟的情况下。可自订的手动方案能够针对特定应用进行流程定制，而成套套件提供简化的工作流程，有助于合规性和操作人员培训。同时，应用层级的转变，例如CAR-T疗法的成熟和再生医学技术的扩展，凸显了对能够维持细胞活力和功能特性的处理方法的需求。这些转变的整合将迫使各机构采用混合策略，以平衡自动化系统的严谨性和扩充性与手动试剂套件的适应性和低初始成本，从而满足临床和临床实验的双重需求。

透过调整供应商策略、在地化措施和库存管理，应对关税主导的采购压力，并保障产品品质和供应。

美国关税的实施为脐带血加工产品相关企业的筹资策略、供应链配置和成本管理带来了复杂的影响。关税对进口零件和整套系统的影响各不相同，这将改变供应商的选择考量，促使买家寻求供应商多元化、探索近岸外包方案并重新评估库存策略。对于依赖全球供应链取得专用零件（例如无菌一次性组件、离心机试剂组）的製造商而言，关税带来的成本压力可能会加速其寻找替代供应商或重新设计以降低关税风险的进程。

为因应此局面，一些机构可能会采取策略性储备关键耗材或重新谈判长期合约以稳定单位成本。另一些机构则可能采取在地化策略，例如与国内委託製造合作或投资区域组装能力，以降低关税风险，同时保持技术专长。关税环境也将影响与终端用户的价格谈判，尤其是预算有限的医院和研究机构。最终，关税将成为营运弹性规划的催化剂，促使采购、合规和产品开发团队之间加强合作，以控制总体拥有成本，同时确保加工耗材和系统的品质和可用性。

对产品架构、治疗用途、最终用户画像、加工技术、服务模式和样品所有权框架进行全面的细分映射

透过细緻的细分视角，我们揭示了不同产品类型、应用、最终用户、处理方法、服务供应商和样本所有权模式下的差异化需求驱动因素和采购行为。基于产品类型的分析区分了自动化系统和手动套件，其中自动化系统进一步细分为封闭式系统和开放式系统；手动试剂套件则区分了可自订通讯协定和预包装套件。按应用领域划分，我们探讨了免疫疗法、再生医学和移植领域。免疫疗法包括CAR-T疗法和NK细胞扩增，再生医学包括组织工程和创伤治疗，移植领域包括造血干细胞和间质干细胞的应用。这种应用层面的细分清晰地表明，处理精确度和细胞完整性是至关重要的。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 利用脐带血进行细胞治疗和再生医学的需求日益增长
  • 创新自动化处理技术，最大限度地提高脐带血干细胞产量
  • 整合人工智慧和机器学习技术，以提高脐带血处理后的品管和活力评估。
  • 扩大生技公司与脐带血库之间的合作，以扩大储存和分发网络
  • 新兴的公私合营模式旨在提高脐带血库服务的可及性
  • 各大市场正逐步改善监管法规，以实现统一的处理标准和认证要求。
  • 开发用于现场脐带血采集和处理的可携式即时检验（POC）处理设备
  • 提高封闭式处理套件的使用率，以最大限度地减少污染并提高脐带血单位的临床效用
  • 体外干细胞扩增技术的进步提高了单份脐带血单位的治疗细胞剂量
  • 在资源匮乏的环境中，采取节省成本的策略来推进脐带血微处理解决方案。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8.脐带血处理产品市场（依产品类型划分）

  • 自动化系统
    • 封闭式系统
    • 开放系统
  • 手册套件
    • 可自订通讯协定
    • 预包装套件

9. 按应用分類的脐带血处理产品市场

  • 免疫疗法
    • CAR-T疗法
    • NK细胞增殖
  • 再生医学
    • 组织工程
    • 创伤治疗
  • 移植
    • 造血干细胞
    • 间质干细胞

第十章 依最终用户分類的脐带血处理产品市场

  • 生技公司
    • 大型製药公司
    • 小型企业
  • 医院和诊所
    • 大学医院
    • 社区医院
  • 研究所
    • CRO
    • 大学

第十一章 依加工方法分類的脐带血加工产品市场

  • 细胞分离
    • CD34 选择
    • 红血球清除
  • 体积减少
    • 离心
    • 过滤

第十二章 脐带血处理产品市场（依服务供应商划分）

  • 合约服务
    • CRO
    • TPL
  • 内部

第十三章 依样本类型分類的脐带血处理产品市场

  • 私人银行
    • 自体血库
    • 家庭银行
  • 大众银行

第十四章 脐带血处理产品市场（依地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 脐带血处理产品市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 各国脐带血处理产品市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Cord Blood Registry, LLC
    • Cryo-Cell International, Inc.
    • ViaCord, LLC
    • Americord Registry LLC
    • China Cord Blood Corporation
    • Vita 34 AG
    • StemCyte, Inc.
    • LifeCell International Pvt. Ltd.
    • Cordlife Group Limited
    • Cord Blood America, Inc.
Product Code: MRR-6849E8ED80B7

The Umbilical Cord Blood Processing Products Market is projected to grow by USD 3.98 billion at a CAGR of 11.27% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.69 billion
Estimated Year [2025] USD 1.89 billion
Forecast Year [2032] USD 3.98 billion
CAGR (%) 11.27%

Framing the strategic context for umbilical cord blood processing products amid clinical innovation, quality demands, and evolving operational priorities

The introduction establishes the context for a rapidly evolving domain where umbilical cord blood processing products intersect clinical innovation, regulatory evolution, and operational modernization. Advances in cell-based therapies and regenerative medicine have elevated the importance of precise, efficient, and sterility-assured processing solutions, prompting stakeholders across clinical, research, and commercial settings to reassess workflows from collection to storage. Simultaneously, the industry faces intensified scrutiny around quality controls, traceability, and scalability, leading organizations to reconsider traditional manual approaches in favor of technologies that promise reproducibility and reduced contamination risk.

Against this backdrop, the report frames key thematic drivers shaping strategic choices: integration of automated systems within existing laboratory infrastructures; differentiation between closed and open-system architectures; and the trade-offs between customizable manual kit protocols and prepackaged kits that prioritize speed and compliance. It also establishes a lens for evaluating end-user needs spanning biotechnology companies, hospitals and clinics, and research institutions, each with distinct priorities linked to therapeutic pipelines, clinical throughput, and investigational activity. This foundational overview prepares executives to interpret subsequent analysis through a pragmatic lens that emphasizes operational readiness, regulatory alignment, and the potential for cross-sector collaboration.

How technological automation, protocol flexibility, and therapeutic advances are driving hybrid strategies and reshaping processing workflows across clinical and research settings

Transformative shifts across technology, workflow design, and policy are redefining expectations for cord blood processing solutions. Automation is no longer a niche enhancement but a strategic lever that directly affects reproducibility, labor utilization, and contamination control. Closed automated systems, designed to minimize operator intervention and maintain aseptic barriers, are increasingly attractive to clinical laboratories pursuing higher throughput and consistent outcomes. By contrast, open systems retain flexibility for bespoke protocols and process adjustments, keeping them relevant for research settings and small-scale clinical operations where method customization is essential.

Manual kits continue to play a complementary role, particularly where protocols demand adaptability or where capital expenditure constraints delay automation adoption. Customizable manual protocols enable process tailoring for niche applications, while prepackaged kits deliver simplified workflows that aid compliance and operator training. Concurrently, application-level shifts such as the maturation of CAR-T therapies and expanding regenerative medicine techniques emphasize the need for processing methods that preserve cell viability and functional characteristics. These converging shifts compel organizations to adopt hybrid strategies that balance the rigor and scalability of automated systems with the adaptability and lower initial costs of manual kits, thereby positioning them to respond to both clinical and investigational demands.

Navigating tariff-driven procurement pressures by recalibrating supplier strategies, localization efforts, and inventory practices to protect quality and availability

The imposition of tariffs in the United States introduces a complex overlay to procurement strategies, supply chain configurations, and cost management for firms involved in cord blood processing products. Tariff measures affect imported components and complete systems differently, altering vendor selection calculus and encouraging buyers to reassess supplier diversification, nearshoring options, and inventory policies. For manufacturers that rely on global supply chains for specialized components such as sterile single-use assemblies, centrifuge rotors, or reagent kits, tariff-related cost pressures may accelerate efforts to qualify alternative suppliers or to reconfigure designs to reduce tariff exposure.

In response, some organizations are likely to adopt strategic stockpiling of critical consumables or to renegotiate long-term contracts to stabilize unit costs. Others may pursue localization strategies, including partnerships with domestic contract manufacturers or investments in regional assembly capabilities that mitigate tariff risk while preserving access to technological expertise. The tariff environment also affects pricing negotiations with end users, particularly for hospitals and research institutions operating under constrained budgets. Ultimately, tariffs act as a catalyst for operational resilience planning, driving a closer alignment between procurement, regulatory compliance, and product development teams to manage total cost of ownership while maintaining quality and availability of processing supplies and systems.

Comprehensive segmentation mapping across product architectures, therapeutic uses, end-user profiles, processing techniques, service models, and sample ownership frameworks

A nuanced segmentation view reveals differentiated demand drivers and procurement behaviors across product types, applications, end users, processing methods, service providers, and sample ownership models. Based on product type, analysis distinguishes between Automated Systems and Manual Kits, with Automated Systems further categorized into Closed Systems and Open Systems, and Manual Kits differentiated into Customizable Protocols and Prepackaged Kits; these distinctions illuminate trade-offs between throughput, sterility assurance, and protocol flexibility. Based on application, the landscape is examined across Immunotherapy, Regenerative Medicine, and Transplantation, where Immunotherapy includes CAR-T Therapy and NK Cell Expansion, Regenerative Medicine covers Tissue Engineering and Wound Healing, and Transplantation encompasses Hematopoietic Stem Cell and Mesenchymal Stem Cell uses; this application-level breakdown clarifies where processing fidelity and cell integrity are most mission-critical.

Based on end user, the market comprises Biotechnology Companies, Hospitals And Clinics, and Research Institutions, with Biotechnology Companies subdivided into Large Pharma and SMEs, Hospitals And Clinics split into Academic Hospitals and Community Hospitals, and Research Institutions incorporating Contract Research Organizations and Universities; these end-user definitions help explain procurement cycles, regulatory expectations, and adoption velocity. Based on processing method, analysis identifies Cell Separation and Volume Reduction, with Cell Separation including CD34 Selection and Red Cell Depletion, and Volume Reduction differentiating Centrifugation and Filtration; understanding these methodological choices is essential for evaluating equipment and consumable compatibility. Based on service provider, distinctions between Contract Services and In-House operations highlight the roles of Contract Research Organizations and Third-Party Laboratories in scaling specialized processing, while based on sample type, the market differentiates Private Banks and Public Banks, with Private Banks further classified into Autologous Banks and Family Banks; this ownership segmentation affects quality standards, custodial responsibilities, and commercial models. Together, these intersecting dimensions provide a comprehensive lens to align product design, regulatory compliance, and go-to-market approaches with distinct customer needs.

How regional regulatory regimes, clinical priorities, and banking models shape procurement choices and vendor strategies across major global markets

Regional dynamics exert a powerful influence on procurement preferences, regulatory requirements, and collaborative ecosystems. In the Americas, a concentration of advanced therapeutic development, active clinical trial networks, and a mature private banking sector favors early adoption of automated and closed systems that support regulated clinical workflows and large-scale processing demands. Transitioning from this regional profile, Europe, Middle East & Africa presents a heterogeneous mix of markets where regulatory harmonization and public bank infrastructures in some countries coexist with rapidly growing private banking interest in others; this environment encourages modular solutions that can be adapted to varied compliance regimes and resource constraints. Meanwhile, Asia-Pacific exhibits a blend of high-volume clinical populations, expanding biotech investment, and governmental initiatives that support regenerative medicine research, all of which create demand for both high-throughput automated platforms and accessible manual kits suited to decentralized facilities.

Across regions, differences in reimbursement frameworks, clinical trial regulatory pathways, and the prevalence of public versus private cord blood banks shape procurement and deployment timelines. For instance, regions with robust public bank networks may prioritize processing methods that optimize cell yield for transplantation, while markets with accelerating immunotherapy pipelines prioritize technologies that preserve functional cell characteristics relevant to ex vivo expansion. These regional nuances encourage vendors and service providers to pursue differentiated market entry strategies, collaborate with local laboratories and academic centers for validation studies, and design service offerings that reflect regional expectations for quality assurance, traceability, and customer support.

Company-level differentiation driven by integrated system-consumable design, service expansion, supply resilience, and strategic validation partnerships

Key company-level dynamics center on innovation in system design, consumable affordability, service breadth, and strategic partnerships that bridge clinical and research needs. Leading organizations differentiate themselves through integrated offerings that combine hardware platforms, single-use consumables, and validated workflows to reduce adoption friction and ensure reproducible outcomes. Strategic collaborations between system manufacturers and contract laboratories or academic centers accelerate validation across varied use cases and provide third-party evidence of performance under real-world conditions. Meanwhile, companies that expand service portfolios to include contract processing, method validation, and training services create sticky relationships with end users who prioritize turnkey solutions.

Operational excellence in manufacturing, supply chain resilience, and regulatory support are decisive competitive levers. Firms that invest in scalable production capacity for sterile disposables and that maintain multiple qualified suppliers for critical components mitigate disruption risks and protect customer continuity. At the same time, commercial strategies that address differentiated buyer segments-such as offering compact, cost-efficient kits for community hospitals and modular automated platforms for large research centers-enhance market reach. Finally, intellectual property around cell selection technologies, closed-system interfaces, and assay-compatible consumables can provide defensible differentiation, while transparent quality management and third-party certifications reinforce trust among clinical and research customers.

Actionable strategic steps for executives to balance automation scale, supply resilience, validation transparency, and service-led adoption pathways

Industry leaders should adopt a pragmatic mix of strategic investments and tactical adjustments to capture value in a complex, evolving landscape. First, prioritize modular automation that allows incremental deployment: organizations can phase in closed-system modules for high-volume workflows while retaining open-system capabilities for prototyping and method development. This approach preserves flexibility and manages capital intensity. Second, develop dual sourcing and regional supplier qualification programs to reduce tariff exposure and supply chain vulnerability, and couple those programs with contingency inventory policies that balance working capital with availability of critical consumables.

Third, invest in rigorous validation studies and publish technical performance data to shorten procurement cycles and build trust among hospital procurement teams and research institutions. Fourth, expand service portfolios to include method transfer support, training, and contract processing options that lower adoption barriers and create recurring revenue streams. Fifth, align product roadmaps with application-specific requirements-such as protocols optimized for CAR-T manufacturing or for mesenchymal stem cell preservation-ensuring that design choices reflect the sensitivity of target cell populations. Finally, cultivate strategic partnerships with banks, academic centers, and biotechnology companies to co-develop workflows and to secure early adopters for new platform releases, thereby accelerating field validation and commercial traction.

Methodological framework combining multi-stakeholder primary research, technical validation, and cross-checked analytical procedures to ensure robust insights

The research methodology combines a multi-source evidence base with rigorous validation steps to ensure analytical integrity and operational relevance. Primary research included structured consultations with stakeholders across vendors, hospital laboratories, research institutions, and contract service providers to capture experiential insights into procurement drivers, technology selection criteria, and operational pain points. These qualitative inputs were triangulated with technical specifications, regulatory documentation, and validation reports to assess product capabilities, workflow compatibility, and quality systems. In parallel, secondary research synthesized publicly available literature, patents, and clinical trial registries to map application trends and technological trajectories.

Analytical procedures emphasized cross-validation and scenario analysis. For example, technology capability assessments were reviewed against third-party validation studies and user-reported performance data to reconcile controlled-lab claims with real-world performance. Segmentation constructs were stress-tested through interviews with representative end users to ensure that categories-spanning product type, application, end user, processing method, service provider, and sample type-reflect practical decision-making frames. Finally, sensitivity checks and expert review panels were used to surface divergent viewpoints and to refine interpretations, ensuring that conclusions are grounded in a balanced appraisal of technological potential, operational constraints, and regulatory context.

Strategic synthesis emphasizing flexibility, validation, supply resilience, and collaboration as the foundation for sustained adoption and clinical impact

In conclusion, the domain of umbilical cord blood processing products is at an inflection point defined by the interplay of automation, therapeutic innovation, and supply chain realignment. Organizations that adopt flexible strategies-combining the reproducibility and contamination control benefits of closed automated systems with the adaptability and cost advantages of manual kits-will be better positioned to meet diverse user needs across clinical and research settings. Regional and tariff-driven dynamics require deliberate supply chain planning and localized partnership models to maintain continuity and control total cost exposure. Moreover, companies that invest in transparent validation, integrated service offerings, and targeted product roadmaps aligned with specific applications such as immunotherapy and transplantation will create durable value for customers.

Looking forward, the most resilient players will be those that incorporate iterative learning into product development, maintain diversified sourcing, and actively collaborate with clinical and academic partners to validate performance in situ. By emphasizing operational readiness, regulatory alignment, and customer-centric services, stakeholders can convert technical capabilities into sustained adoption and improved patient and research outcomes. This concluding synthesis underscores the importance of strategic adaptability as the cornerstone of long-term success in a rapidly evolving field.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising demand for cell therapy and regenerative medicine applications using cord blood
  • 5.2. Innovations in automated processing technologies that maximize stem cell yield from umbilical cord blood
  • 5.3. Integration of artificial intelligence and machine learning to improve quality control and viability assessment of processed cord blood
  • 5.4. Increasing partnerships between biotechnology firms and cord blood banks to expand storage and distribution networks
  • 5.5. Emergence of private public collaborative models to enhance accessibility of cord blood banking services
  • 5.6. Regulatory evolution toward harmonized processing standards and accreditation requirements across key markets
  • 5.7. Development of portable point of care processing devices for on site umbilical cord blood collection and handling
  • 5.8. Growing adoption of closed system processing kits to minimize contamination and improve clinical usability of cord blood units
  • 5.9. Advances in ex vivo stem cell expansion techniques to increase therapeutic cell doses from single cord blood units
  • 5.10. Cost reduction strategies driving microvolume processing solutions for umbilical cord blood in resource limited settings

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Umbilical Cord Blood Processing Products Market, by Product Type

  • 8.1. Automated Systems
    • 8.1.1. Closed Systems
    • 8.1.2. Open Systems
  • 8.2. Manual Kits
    • 8.2.1. Customizable Protocols
    • 8.2.2. Prepackaged Kits

9. Umbilical Cord Blood Processing Products Market, by Application

  • 9.1. Immunotherapy
    • 9.1.1. CAR-T Therapy
    • 9.1.2. NK Cell Expansion
  • 9.2. Regenerative Medicine
    • 9.2.1. Tissue Engineering
    • 9.2.2. Wound Healing
  • 9.3. Transplantation
    • 9.3.1. Hematopoietic Stem Cell
    • 9.3.2. Mesenchymal Stem Cell

10. Umbilical Cord Blood Processing Products Market, by End User

  • 10.1. Biotechnology Companies
    • 10.1.1. Large Pharma
    • 10.1.2. SMEs
  • 10.2. Hospitals And Clinics
    • 10.2.1. Academic Hospitals
    • 10.2.2. Community Hospitals
  • 10.3. Research Institutions
    • 10.3.1. Contract Research Organizations
    • 10.3.2. Universities

11. Umbilical Cord Blood Processing Products Market, by Processing Method

  • 11.1. Cell Separation
    • 11.1.1. CD34 Selection
    • 11.1.2. Red Cell Depletion
  • 11.2. Volume Reduction
    • 11.2.1. Centrifugation
    • 11.2.2. Filtration

12. Umbilical Cord Blood Processing Products Market, by Service Provider

  • 12.1. Contract Services
    • 12.1.1. Contract Research Organizations
    • 12.1.2. Third-Party Laboratories
  • 12.2. In-House

13. Umbilical Cord Blood Processing Products Market, by Sample Type

  • 13.1. Private Banks
    • 13.1.1. Autologous Banks
    • 13.1.2. Family Banks
  • 13.2. Public Banks

14. Umbilical Cord Blood Processing Products Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Umbilical Cord Blood Processing Products Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Umbilical Cord Blood Processing Products Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Cord Blood Registry, LLC
    • 17.3.2. Cryo-Cell International, Inc.
    • 17.3.3. ViaCord, LLC
    • 17.3.4. Americord Registry LLC
    • 17.3.5. China Cord Blood Corporation
    • 17.3.6. Vita 34 AG
    • 17.3.7. StemCyte, Inc.
    • 17.3.8. LifeCell International Pvt. Ltd.
    • 17.3.9. Cordlife Group Limited
    • 17.3.10. Cord Blood America, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PROCESSING METHOD, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PROCESSING METHOD, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY SERVICE PROVIDER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY SERVICE PROVIDER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY AUTOMATED SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY AUTOMATED SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY AUTOMATED SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY AUTOMATED SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY AUTOMATED SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY AUTOMATED SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY AUTOMATED SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CLOSED SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CLOSED SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CLOSED SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CLOSED SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CLOSED SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CLOSED SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY OPEN SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY OPEN SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY OPEN SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY OPEN SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY OPEN SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY OPEN SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY MANUAL KITS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY MANUAL KITS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY MANUAL KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY MANUAL KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY MANUAL KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY MANUAL KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY MANUAL KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY MANUAL KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CUSTOMIZABLE PROTOCOLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CUSTOMIZABLE PROTOCOLS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CUSTOMIZABLE PROTOCOLS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CUSTOMIZABLE PROTOCOLS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CUSTOMIZABLE PROTOCOLS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CUSTOMIZABLE PROTOCOLS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PREPACKAGED KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PREPACKAGED KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PREPACKAGED KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PREPACKAGED KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PREPACKAGED KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PREPACKAGED KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CAR-T THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CAR-T THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CAR-T THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CAR-T THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY NK CELL EXPANSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY NK CELL EXPANSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY NK CELL EXPANSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY NK CELL EXPANSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY NK CELL EXPANSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY NK CELL EXPANSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY REGENERATIVE MEDICINE, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY REGENERATIVE MEDICINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY REGENERATIVE MEDICINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY REGENERATIVE MEDICINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY REGENERATIVE MEDICINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY REGENERATIVE MEDICINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY REGENERATIVE MEDICINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY TISSUE ENGINEERING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY TISSUE ENGINEERING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY TISSUE ENGINEERING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY TISSUE ENGINEERING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY TISSUE ENGINEERING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY TISSUE ENGINEERING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY WOUND HEALING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY WOUND HEALING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY WOUND HEALING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY WOUND HEALING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY WOUND HEALING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY WOUND HEALING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY TRANSPLANTATION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY TRANSPLANTATION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY TRANSPLANTATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY TRANSPLANTATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY TRANSPLANTATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY TRANSPLANTATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY TRANSPLANTATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY TRANSPLANTATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY HEMATOPOIETIC STEM CELL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY HEMATOPOIETIC STEM CELL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY HEMATOPOIETIC STEM CELL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY HEMATOPOIETIC STEM CELL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY HEMATOPOIETIC STEM CELL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY HEMATOPOIETIC STEM CELL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY MESENCHYMAL STEM CELL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY MESENCHYMAL STEM CELL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY MESENCHYMAL STEM CELL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY MESENCHYMAL STEM CELL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY MESENCHYMAL STEM CELL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY MESENCHYMAL STEM CELL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY LARGE PHARMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY LARGE PHARMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY LARGE PHARMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY LARGE PHARMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY LARGE PHARMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY LARGE PHARMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY SMES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY SMES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY SMES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY SMES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY SMES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY SMES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY HOSPITALS AND CLINICS, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY ACADEMIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY ACADEMIC HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY ACADEMIC HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY ACADEMIC HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY ACADEMIC HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY ACADEMIC HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY COMMUNITY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY COMMUNITY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY COMMUNITY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY COMMUNITY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY COMMUNITY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY COMMUNITY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY RESEARCH INSTITUTIONS, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY UNIVERSITIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY UNIVERSITIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY UNIVERSITIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY UNIVERSITIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY UNIVERSITIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY UNIVERSITIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PROCESSING METHOD, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PROCESSING METHOD, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CELL SEPARATION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CELL SEPARATION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CELL SEPARATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CELL SEPARATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CELL SEPARATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CELL SEPARATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CELL SEPARATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CELL SEPARATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CD34 SELECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CD34 SELECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CD34 SELECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CD34 SELECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CD34 SELECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CD34 SELECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY RED CELL DEPLETION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY RED CELL DEPLETION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY RED CELL DEPLETION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY RED CELL DEPLETION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY RED CELL DEPLETION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY RED CELL DEPLETION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY VOLUME REDUCTION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY VOLUME REDUCTION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY VOLUME REDUCTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY VOLUME REDUCTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY VOLUME REDUCTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY VOLUME REDUCTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY VOLUME REDUCTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY VOLUME REDUCTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CENTRIFUGATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CENTRIFUGATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CENTRIFUGATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CENTRIFUGATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CENTRIFUGATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CENTRIFUGATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY FILTRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY FILTRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY FILTRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY FILTRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY FILTRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY FILTRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY SERVICE PROVIDER, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY SERVICE PROVIDER, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CONTRACT SERVICES, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CONTRACT SERVICES, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CONTRACT SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CONTRACT SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CONTRACT SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CONTRACT SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CONTRACT SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CONTRACT SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY THIRD-PARTY LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY THIRD-PARTY LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY THIRD-PARTY LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY THIRD-PARTY LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY THIRD-PARTY LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY THIRD-PARTY LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY IN-HOUSE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY IN-HOUSE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY IN-HOUSE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY IN-HOUSE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY IN-HOUSE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY IN-HOUSE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PRIVATE BANKS, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PRIVATE BANKS, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PRIVATE BANKS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PRIVATE BANKS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PRIVATE BANKS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PRIVATE BANKS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PRIVATE BANKS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PRIVATE BANKS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY AUTOLOGOUS BANKS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY AUTOLOGOUS BANKS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY AUTOLOGOUS BANKS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY AUTOLOGOUS BANKS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY AUTOLOGOUS BANKS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY AUTOLOGOUS BANKS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY FAMILY BANKS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY FAMILY BANKS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY FAMILY BANKS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY FAMILY BANKS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL UMBILICAL CORD BLOOD PROCES